Regenxbio (RGNX) Enterprise Value (2015 - 2026)

Regenxbio's Enterprise Value history runs 12 years deep, the most recent figure standing at -$230.1 million for Q4 2025.

• In Q4 2025, Enterprise Value rose 1.97% year-over-year to -$230.1 million; the TTM figure through Dec 2025 stood at -$230.1 million (up 1.97% YoY), while the FY2025 annual figure was -$230.1 million, up 1.97% from the prior year.
• Enterprise Value for Q4 2025 stood at -$230.1 million, up from -$274.2 million in the prior quarter.
• The five-year high for Enterprise Value was -$230.1 million in Q4 2025, with the low at -$457.4 million in Q4 2021.
• The 5-year median for Enterprise Value is -$327.6 million (2023), against an average of -$330.0 million.
• The sharpest annual moves came in 2021 and 2023: Enterprise Value tumbled 57.88% in 2021, then advanced 24.51% in 2023.
• Regenxbio's Enterprise Value stood at -$457.4 million in 2021, then grew by 20.29% to -$364.6 million in 2022, then rose by 24.51% to -$275.3 million in 2023, then climbed by 14.74% to -$234.7 million in 2024, then climbed by 1.97% to -$230.1 million in 2025.
• Business Quant data shows RGNX's Enterprise Value at -$230.1 million in Q4 2025, -$274.2 million in Q3 2025, and -$323.3 million in Q2 2025.